MedTrace Logo

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

NCT04530682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 163

Last updated 2024-04-30

No results posted yet for this study

Summary

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

Conditions

  • Chronic Inflammatory Rheumatism

Interventions

BIOLOGICAL

Biological samples

Serum and plasma samples. At baseline, 6, 12 and 24 months

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

  • French Society of Rheumatology

    collaborator OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2022-06-23
Completion
2024-02-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530682 on ClinicalTrials.gov